← All workflows

Pharma Reg Summary

Pharma Regulatory Summaries in Minutes, Not Hours

12 minutes with CaseMark

Fast lane

We have it from here.

Choose the fast one-off run here, or jump into the workspace when you want saved history, revisions, and a fuller matter workflow.

Run this once here

Best for a quick one-off job. Add your email, upload the files, and we'll run the workflow and send the result to your inbox.

1. Add your email so we know where to send the result.

2. Upload the files you want analyzed.

3. Run the workflow and we'll take it from there.

Use in Workspace

Best for ongoing matters

Save and reopen matters, keep documents together, refine the output, rerun with changes, and export or share polished work product when you're done.

Open in Workspace

Need more context?

Scroll for the workflow details below if you want to review what this run handles, what documents help, and what the output looks like.

If this is part of a live matter, the workspace is the better fit: you can keep your documents together, revisit the result, and keep working without starting from scratch.

Jump to detailsOpen in Workspace

Start here

Run this workflow now

Best for a fast one-off run. Add your email, upload the files, and we'll deliver the result without sending you into the full app.

Workflow

Pharma Reg Summary

Step 1 · Deliver to

Step 3 · Run this workflow

Workflow

Pharma Reg Summary

Overview

CaseMark's Pharmaceutical Regulatory Compliance Summary skill transforms complex FDA filings, patent portfolios, and commercial activity records into structured, actionable compliance summaries. The AI analyzes drug approval pathways, patent and IP regulatory intersections, and marketing compliance obligations to deliver comprehensive reports that would traditionally require extensive manual review across multiple regulatory domains.

Pharmaceutical regulatory compliance demands simultaneous mastery of FDA approval pathways, patent and IP strategy, and promotional compliance rules. Attorneys and compliance professionals spend days manually cross-referencing filings, tracking post-market obligations, and mapping patent intersections—often across fragmented document sets and evolving regulatory guidance. The risk of missing a critical deadline or compliance gap is significant and costly.

CaseMark automates the creation of structured pharmaceutical regulatory compliance summaries by analyzing your regulatory filings, product portfolios, and commercial activity records in parallel. The AI maps FDA approval requirements, Orange Book and Hatch-Waxman intersections, and promotional compliance obligations into a single actionable report with per-product checklists, risk flags, and remediation recommendations—delivering in minutes what previously took days of expert review.

How it works

  1. 1. Upload your regulatory filings, product portfolio documents, and commercial activity records

  2. 2. AI analyzes FDA pathways, patent intersections, and promotional compliance requirements

  3. 3. Review the structured compliance summary with per-product checklists and risk flags

  4. 4. Export the final report in your preferred format (DOCX, PDF)

What you get

  • Drug Approval & Post-Market Obligations Summary

  • Patent & IP Regulatory Intersections Analysis

  • Marketing & Promotional Compliance Review

  • Per-Product Compliance Checklists

  • Risk Assessment & Remediation Recommendations

What it handles

  • Structured FDA approval pathway analysis across NDA, ANDA, and BLA submissions

  • Patent and IP regulatory intersection mapping including Orange Book and Hatch-Waxman frameworks

  • Marketing and promotional compliance review covering off-label, DTC, and Anti-Kickback rules

  • Post-market obligation tracking with PMR/PMC deadlines and escalation triggers

  • Per-product compliance checklists aligned to 21 CFR requirements

  • Expedited pathway assessment with confirmatory trial milestone tracking

Required documents

  • Regulatory Filings

    Pending or active NDA, ANDA, BLA, or IND submissions and related FDA correspondence

    .pdf, .docx

  • Product Portfolio Documentation

    Marketed products, pipeline compounds, therapeutic area details, and patent listings

    .pdf, .docx, .xlsx

  • Commercial Activity Records

    Speaker program agreements, DTC campaign materials, consulting arrangements, and promotional materials

    .pdf, .docx

Supporting documents

  • Compliance History

    Warning letters, consent decrees, audit findings, and prior remediation documentation

    .pdf, .docx

  • Post-Market Commitment Tracking

    PMR/PMC status reports, REMS documentation, and FAERS reporting records

    .pdf, .docx, .xlsx

  • Patent and Exclusivity Records

    Orange Book listings, exclusivity certifications, and Paragraph IV certification correspondence

    .pdf, .docx

Why teams use it

Dramatically reduce the time spent compiling FDA compliance overviews from days to minutes

Ensure comprehensive coverage across approval pathways, patent strategy, and promotional compliance in a single unified summary

Identify compliance gaps and risk areas with per-product checklists tied to specific 21 CFR requirements

Standardize regulatory summary formats across your organization for consistent submission readiness assessments

Questions

What types of pharmaceutical regulatory documents can CaseMark analyze?

CaseMark can process NDA, ANDA, and BLA submissions, IND filings, post-approval commitments, warning letters, consent decrees, audit findings, speaker program documentation, and DTC campaign materials. The AI is trained to extract compliance-relevant information from a wide range of pharmaceutical regulatory documents.

Does CaseMark cover both brand and generic drug regulatory pathways?

Yes. CaseMark generates compliance summaries for NDA 505(b)(1) full applications, ANDA 505(j) generic applications including Paragraph IV certifications, BLA 351(a) biologics applications, and expedited pathways such as Breakthrough Therapy and Accelerated Approval. Each pathway receives tailored analysis of requirements and common pitfalls.

How does CaseMark handle Hatch-Waxman and Orange Book analysis?

CaseMark maps patent and IP regulatory intersections by analyzing Orange Book listings under 21 CFR 314.53, exclusivity periods, and Hatch-Waxman framework implications. The AI identifies potential certification issues, exclusivity windows, and strategic considerations for both innovator and generic applicants.

Can CaseMark identify promotional compliance risks like off-label marketing?

Absolutely. CaseMark reviews commercial activities against FDA promotional compliance rules, including off-label promotion restrictions, DTC advertising requirements, Anti-Kickback Statute considerations, and speaker program compliance. The summary flags potential risk areas and recommends remediation steps.

How current is CaseMark's pharmaceutical regulatory knowledge?

CaseMark's AI is built on comprehensive pharmaceutical regulatory frameworks including current FDA guidance, 21 CFR requirements, and established compliance standards. While CaseMark provides powerful first-draft analysis, we always recommend attorney review to confirm alignment with the latest regulatory developments.

How long does it take to generate a pharmaceutical regulatory compliance summary?

CaseMark typically generates a comprehensive regulatory compliance summary in approximately 10-15 minutes, depending on the volume and complexity of uploaded documents. This replaces what traditionally takes days or weeks of manual review and drafting.

Related

30b6 Corporate Rep

Master 30(b)(6) Depositions in Minutes, Not Hours

30b6 Deposition

Master 30(b)(6) Depositions in Minutes, Not Hours

Abstract of Judgment

Draft Judgment Abstracts in Minutes, Not Hours